Yahoo Web Search

Search results

1. • Merck Study of Keytruda With Chemotherapy in Endometrial Cancer Fails to Meet Endpoint

     Morningstar· 4 days ago

     Merck was hit with a setback in its efforts to expand its blockbuster cancer immunotherapy Keytruda after a late-stage study of its use in combination with chemotherapy to ...

2. • 

     Merck's endometrial cancer therapy fails trial

     Reuters via Yahoo News· 4 days ago

     The drugmaker's Keytruda therapy in combination with chemotherapy was being evaluated in about 1,095 patients with high-risk endometrial cancer after...

3. • Merck stops skin cancer combination therapy testing in late-stage study

     Reuters via Yahoo Finance· 8 hours ago

     May 13 (Reuters) - Merck said on Monday it had discontinued the arm of a late-stage study, which tested an experimental antibody-based drug with its blockbuster immunotherapy Keytruda ...

4. • Merck Study of Keytruda With Chemotherapy in Endometrial Cancer Fails to Meet Endpoint

     Market Watch· 4 days ago

     Merck was hit with a setback in its efforts to expand its blockbuster cancer immunotherapy Keytruda after a late-stage study of its use in combination with chemotherapy to ...

5. • 

     Pipeline Moves: Phase III completion for Corcept’s relaorilant

     Clinical Trials Arena via Yahoo Finance· 11 hours ago

     The purpose of the open-label study was to evaluate Stivarga plus Merck’s Keytruda (pembrolizumab)...

6. • 

     Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates

     Zacks via Yahoo Finance· 3 days ago

     Iovance (IOVA) reports mixed first-quarter results. Shares gain on encouraging initial demand for...

7. • 

     Pharma Stock Roundup: PFE DMD Study Patient Death, FDA Panel Meet for LLY's Donanemab

     Zacks via Yahoo Finance· 3 days ago

     Pfizer (PFE) reports the death of a participant in a mid-stage study of its Duchenne drug. An FDA...

8. • 

     Is Eli Lilly Stock A Better Pick Over Amgen?

     Forbes· 14 hours ago

     Also, Eli Lilly has seen a better revenue growth and is more profitable. There is more to the comparison, and in the sections below, we discuss why we...

9. • Merck's endometrial cancer therapy fails trial

     AOL· 4 days ago

     The drugmaker's Keytruda therapy in combination with chemotherapy was being evaluated in about 1,095 patients with high-risk endometrial cancer after surgery. The trial did ...

10. • Medicenna Provides Update on its Presentations at the 2024 ASCO Annual Meeting

      Digital Journal· 8 hours ago

      ASCO has informed the Company that the previously accepted MDNA11 oral abstract has been withdrawn due to alleged violation of their prior publication policy based solely on their review of ...